Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease
07:30am, Tuesday, 17'th Dec 2024
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most co
Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the h
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS
12:01pm, Friday, 13'th Dec 2024
The FDA bestows a Breakthrough Therapy designation to Sanofi's tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis.
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with non-r
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
05:54pm, Thursday, 12'th Dec 2024
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who prepares to leave early next year.
FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates
11:25am, Wednesday, 11'th Dec 2024
The FDA bestows a Fast Track designation to Sanofi's two combination vaccine candidates to prevent influenza and COVID-19 infections.
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
01:00am, Wednesday, 11'th Dec 2024
Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US First non-mRNA combination vaccine candidates that include two already licensed vac
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
02:06pm, Monday, 09'th Dec 2024
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MR
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
11:30am, Saturday, 07'th Dec 2024
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program
08:00am, Friday, 06'th Dec 2024
HOUSTON & SEATTLE--(BUSINESS WIRE)--Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of canc
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
01:30am, Friday, 06'th Dec 2024
Availability of the revised financial statements for Sanofi excluding Opella Paris, France – December 6, 2024. Following the press release on October 21, 2024 and the plan to transfer a 50% controll
BEIJING, Dec. 05, 2024 (GLOBE NEWSWIRE) -- On December 2nd, the Administrative Committee of the Beijing Economic-Technological Development Area (Beijing E-Town) and the Sanofi Group signed a memorandu
BEIJING, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The global pharmaceutical giant Sanofi has once again boosted its investment in Beijing E-Town. On December 2nd, the Administrative Committee of the Beijing
Sanofi to invest $1 bln in insulin production site in Beijing, local authority says
06:36am, Monday, 02'nd Dec 2024
French drugmaker Sanofi plans to invest 1 billion euros ($1.05 billion) to build a new insulin production base in Beijing, a local authority in the city said on Monday, citing a memorandum of understa
Pharma giant Sanofi opens $595 million vaccine facility in Singapore to boost preparedness for potential pandemics
02:56am, Wednesday, 27'th Nov 2024
The facility, known as Modulus, can switch between making different vaccines or treatments in a matter of days. It will contribute about 200 skilled jobs to Singapore, and will be fully operational by
